Alzheimer's Disease And Dementia
Multimarker inflammatory biosignatures are expected to facilitate diagnosis and predict treatment outcomes for various central nervous system disorders, particularly Alzheimer disease and major depressive disorder.
Methylphenidate demonstrated an improvement in apathy vs placebo when measured by the apathy evaluation scale, in addition, methylphenidate showed possible improvement in cognition.
Use of anticholinergic drugs may be tied to a future diagnosis of dementia.
Additional examination of these relationships is warranted to help clarify the complex biologic and psychosocial interactions among Alzheimer disease, malignant melanoma, and nonmelanoma skin cancer.
Results showed that after 18-months, there was no significant statistical difference in cognitive or functional outcomes between those patients taking azeliragon and the placebo group.
About half of adults surveyed expect a man with mild Alzheimer dementia to be discriminated against.
Findings show lower post-surgical mortality among patients with Alzheimer's disease.
Molecular markers can identify changes associated with the disease before clinical onset for young adults with autosomal dominant AD.
Merck announced the discontinuation of the Phase 3 APECS study for the treatment of AD.
Positive beliefs on age may protect against dementia.
The use of DBS in patients with Alzheimer disease is well tolerated and associated with less decline on the CDR-SB.
A study was conducted to assess potential beneficial effects of a lifestyle intervention program on cognition in carriers of the APOE ε4 allele.
Solanezumab does not alter cognitive decline in patients with mild Alzheimer disease.
Brain amyloidosis is associated with certain Alzheimer disease risk variants.
Because of dementia's prolonged disease course, advance care decisions and planning are often overlooked until it is too late.
For patients with mild-to-moderate Alzheimer disease, the use of idalopirdine does not improve cognition.
There is an increased risk of dementia for patients with rheumatic diseases.
A hanful of studies reviewed the different types of interventions to prevent late-life dementia.
Throughout the life course, higher body mass index and obesity are linked to cognitive decline, brain atrophy, reduced white matter and integrity of the blood-brain barrier, and elevated risk for late-onset Alzheimer disease.
It is predicted that by 2060, a total of 15 million American's will have clinical Alzheimer disease or mild cognitive impairment.
Low memory scores are an early marker for amyloid positivity, but not for measuring early Alzheimer's disease.
For improving cognition in a mouse model of AD, combining environmental enrichment and MgT is more effective than either alone.
The findings may be particularly useful at the individual level to determine personalized risk of progression to Alzheimer's dementia.
There is an urgent need for individualized risk assessments for patients with mild cognitive impairment.
The FDA has granted Fast Track status to an investigational agent for the treatment of Alzheimer disease.
Axovant Sciences announced that intepirdine did not meet its primary endpoints.
The APOE ε2/ε3 genotype was associated with a protective effect in women and decreased their AD risk to a greater degree than men.
Some female carriers of the APOE4 gene have a 10-year window where they are more likely to develop Alzheimer's than men.
Lifetime care costs are increased for people with dementia.
Depressive symptoms could be used as an early detection marker of Alzheimer's disease.
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Psychological Therapies May Help Older Adults With Chronic Pain
- Vitamin D: The Only Dietary Supplement Showing Significant Benefit for MS
- Concussion Misdiagnosis Associated With Emergency Department Stay, Injury Type
- Evolution of NEDA: Q&A With Cleveland Clinic's Dr Robert Bermel
- Micronutrient Levels May Be Altered in ADHD
- Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy
- FDA Approves Aimovig for Migraine Prevention
- Solriamfetol Associated With Improvement in Narcolepsy Types 1 and 2
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- Low Income, Singlehood, and Race Tied to Seizure Control in Active Epilepsy
- FNIH Launches Project to Identify Biosignatures of Neurodegenerative, Psychiatric Conditions
- Associations Between Maternal Depression, Support, and Cognitive Development in Offspring
- Alteplase Good for Ischemic Stroke With Unknown Onset Time
- Aerobic and Strength Exercise Doesn't Slow Cognitive Decline